SlideShare a Scribd company logo
1 of 1
Download to read offline
Aim:	
  	
  
To	
  inves)gate	
  how	
  changes	
  in	
  renal	
  arterial	
  pressure	
  and	
  venous	
  
pressure	
  separately	
  and	
  in	
  combina)on	
  affect	
  renal	
  
hemodynamic	
  and	
  re-­‐absorp)ve	
  func)on,	
  in	
  simulated	
  states	
  of	
  
normal,	
  elevated	
  and	
  strongly	
  elevated	
  levels	
  of	
  Angiotensin	
  II	
  
(Ang	
  II).	
  
Background:	
  	
  
Heart	
  failure	
  (HF)	
  is	
  associated	
  with	
  impaired	
  renal	
  func)on.	
  This	
  
has	
  been	
  aCributed	
  to	
  systemic	
  hemodynamic	
  changes:	
  forward	
  
failure	
  causing	
  decreased	
  renal	
  arterial	
  pressure	
  (RAP)	
  and	
  
backward	
  failure	
  causing	
  venous	
  conges)on	
  and	
  increased	
  renal	
  
venous	
  pressure	
  (RVP).	
  	
  
Aus)n	
  Baird1,	
  Branko	
  Braam2	
  and	
  Anita	
  Layton1	
  	
  
1	
  Dept.	
  Mathema)cs,	
  Duke	
  Univ.,	
  Durham,	
  NC,	
  USA	
  and	
  2	
  Div.	
  Nephrology,	
  Dept.	
  Medicine	
  and	
  Dept.	
  Physiology,	
  Univ.	
  of	
  Alberta,	
  Edmonton,	
  AB,	
  Canada	
  
Conclusion:	
  
Our	
  model	
  implicates	
  that	
  a	
  decrease	
  in	
  renal	
  arterial	
  pressure	
  leads	
  to	
  a	
  
decrease	
   in	
   sodium	
   excre)on	
   under	
   normal	
   condi)ons,	
   which	
   becomes	
  
more	
  pronounced	
  when	
  venous	
  pressure	
  is	
  increased.	
  Angiotensin	
  II	
  leads	
  
to	
   a	
   depression	
   of	
   GFR,	
   and	
   to	
   a	
   strong	
   decrease	
   in	
   frac)onal	
   sodium	
  
excre)on.	
   Further	
   studies	
   will	
   be	
   directed	
   to	
   inves)gate	
   the	
   role	
   of	
   the	
  
myogenic	
  response	
  and	
  tubuloglomerular	
  feedback	
  on	
  renal	
  func)on	
  and	
  
response	
  to	
  changes	
  in	
  renal	
  arterial	
  and	
  venous	
  pressures.	
  	
  
	
  
This	
   research	
   was	
   supported	
   in	
   part	
   by	
   NIH	
   grant	
   DK-­‐89066	
   and	
   by	
   NSF	
  
grant	
  DMS1263995	
  
Implica)ons	
  of	
  increased	
  renal	
  venous	
  pressure	
  for	
  renal	
  hemodynamic	
  and	
  
reabsorp)ve	
  func)on	
  studied	
  by	
  a	
  mathema)cal	
  model	
  of	
  the	
  kidney	
  
IM:	
  Inner	
  medulla;	
  CDs:	
  collec)ng	
  ducts;	
  MD:	
  macula	
  densa;	
  PCT:	
  
proximal	
  convoluted	
  tubule;	
  DVR:	
  descending	
  vasa	
  recta;	
  AVR:	
  
ascending	
  vasa	
  recta.	
  
RVP (mmHg)
5 10 15 20
25
30
RAP (mmHg)
80
100
120
SNGFR(nl
min)
0
5
10
15
20
25
30
35
5 10 15 20 25 30
RVP (mmHg)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Sodiumexcretion(umol/min)
baseline
low
high
5 10 15 20 25 30
RVP (mmHg)
50
100
150
200
250
300
350
400
SNBF(nl/min)
baseline
low
high
5 10 15 20 25 30
RVP (mmHg)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
FractionalNaexcretion(%)
baseline
low
high
80 100 120 140 160 180 200
RAP (mmHg)
0
2
4
6
8
10
Sodiumexcretion(umol/min)
baseline
low
high
RVP (mmHg)
5 10 15 20
25
30
RAP (mmHg)
80
100
120
SNGFR(nl
min)
0
5
10
15
20
25
30
35
Inner	
  
stripe	
  
Inner	
  
medulla	
  
Outer	
  
stripe	
  
Renal	
  Venous	
  
Pressure	
  (RVP)	
  
Renal	
  Arterial	
  
Pressure	
  (RAP)	
  
RVP (mmHg)
5 10 15 20
25
30
RAP (mmHg)
80
100
120
FractionalNaexcretion%
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Cortex	
  
RVP (mmHg)
5 10 15 20
25
30
RAP (mmHg)
80
100
120
FractionalNaexcretion%
0.0
0.2
0.4
0.6
0.8
1.0
1.2
RVP (mmHg)
5 10 15 20
25
30
RAP (mmHg)
80
100
120
FractionalNaexcretion%
0.0
0.2
0.4
0.6
0.8
1.0
1.2
High	
  Ang	
  II	
  
Figure	
   2:	
   SNGFR	
   and	
   SNBF,	
   obtained	
   for	
   the	
   superficial	
   nephron,	
   whole	
  
kidney	
  sodium	
  excre)on	
  and	
  frac)onal	
  sodium	
  excre)on	
  dependency	
  on	
  
RVP	
  in	
  normal	
  (baseline),	
  elevated	
  (low)	
  and	
  strongly	
  (high)	
  elevated	
  Ang	
  II	
  
states.	
  RAP	
  =	
  100	
  mmHg	
  for	
  all	
  simula)ons.	
  
RVP (mmHg)
5 10 15 20
25
30
RAP (mmHg)
80
100
120
SNGFR(nl
min)
0
5
10
15
20
25
30
35
Figure	
  3:	
  Effects	
  on	
  SNGFR	
  and	
  frac)onal	
  whole	
  kidney	
  sodium	
  excre)on	
  
upon	
  combined	
  changes	
  of	
  RAP	
  and	
  RVP	
  in	
  normal	
  (baseline),	
  elevated	
  
(low)	
  and	
  very	
  elevated	
  (high)	
  Ang	
  II	
  states.	
  SNGFR	
  reported	
  for	
  the	
  
superficial	
  nephron	
  simula)ons.	
  
Baseline	
  
Low	
  Ang	
  II	
  
Renal	
  Venous	
  
Pressure	
  (RVP)	
  
80 100 120 140 160 180 200
RAP (mmHg)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
FractionalNaexcretion(%)
baseline
low
high
80 100 120 140 160 180 200
RAP (mmHg)
10
20
30
40
50
60
70
SNGFR(nl/min)
baseline
low
high
80 100 120 140 160 180 200
RAP (mmHg)
150
200
250
300
350
400
450
SNBF(nl/min)
baseline
low
high
5 10 15 20 25 30
RVP (mmHg)
0
10
20
30
40
50
60
SNGFR(nl/min)
baseline
low
high
References:	
  
1.	
  R	
  Moss	
  and	
  AT	
  Layton,	
  AJP	
  Renal,	
  2014.	
  
Methods:	
  	
  
We	
  used	
  a	
  published	
  and	
  well-­‐characterized	
  mathema)cal	
  
kidney	
  model	
  incorpora)ng	
  superficial	
  and	
  deep	
  nephrons	
  and	
  
renal	
  hemodynamics,	
  including	
  myogenic	
  response	
  (MR),	
  tubulo-­‐
glomerular	
  feedback	
  (TGF),	
  and	
  segmental	
  sodium	
  handling	
  [1].	
  	
  
Figure	
  1:	
  Single	
  nephron	
  GFR	
  (SNGFR)	
  blood	
  flow	
  (SNBF),	
  both	
  obtained	
  for	
  
the	
  superficial	
  nephron,	
  and	
  whole	
  kidney	
  sodium	
  excre)on	
  and	
  frac)onal	
  
sodium	
  excre)on	
  dependency	
  on	
  renal	
  artery	
  pressure	
  (RAP)	
  in	
  normal	
  
(baseline),	
  elevated	
  (low)	
  and	
  strongly	
  (high)	
  elevated	
  Ang	
  II	
  states.	
  RVP	
  =	
  5	
  
mmHg	
  for	
  all	
  simula)ons.	
  

More Related Content

What's hot

Anti-Hypertensive drugs
Anti-Hypertensive drugsAnti-Hypertensive drugs
Anti-Hypertensive drugsEneutron
 
Calcium Channel Blockers in Hypertension
Calcium Channel Blockers in Hypertension Calcium Channel Blockers in Hypertension
Calcium Channel Blockers in Hypertension Dr Vivek Baliga
 
Positive inotropes, vasopressors, and vasodilators
Positive inotropes, vasopressors, and vasodilatorsPositive inotropes, vasopressors, and vasodilators
Positive inotropes, vasopressors, and vasodilatorsAndrew Ferguson
 
Fusaro - Renal Denervation, current evidence and new technical developments
Fusaro - Renal Denervation, current evidence and new technical developmentsFusaro - Renal Denervation, current evidence and new technical developments
Fusaro - Renal Denervation, current evidence and new technical developmentsSalutaria
 
ARBs USE IN MANAGEMENT OF MYORCARDIAL INFARCTION
ARBs USE IN MANAGEMENT OF MYORCARDIAL INFARCTIONARBs USE IN MANAGEMENT OF MYORCARDIAL INFARCTION
ARBs USE IN MANAGEMENT OF MYORCARDIAL INFARCTIONManasseh Sallau
 
Vasodilator Lecture
Vasodilator LectureVasodilator Lecture
Vasodilator Lectureguest9bc2b8
 
Paradigm hf-trial-ppt-pptx - copia
Paradigm hf-trial-ppt-pptx - copiaParadigm hf-trial-ppt-pptx - copia
Paradigm hf-trial-ppt-pptx - copiaEdgardo Kaplinsky
 
current practice for use of inotropes post adult cardiac surgery
current practice for use of inotropes post adult cardiac surgerycurrent practice for use of inotropes post adult cardiac surgery
current practice for use of inotropes post adult cardiac surgeryAnuj Mehta
 
OSCAR trial - Summary & Results
OSCAR trial - Summary & ResultsOSCAR trial - Summary & Results
OSCAR trial - Summary & Resultstheheart.org
 
Inotropes and their choice
Inotropes and their choiceInotropes and their choice
Inotropes and their choiceDharmraj Singh
 
Telsarta-A final-01-04-16
Telsarta-A  final-01-04-16Telsarta-A  final-01-04-16
Telsarta-A final-01-04-16Muhammad Aun
 

What's hot (20)

Tolvaptan
TolvaptanTolvaptan
Tolvaptan
 
Are+all+sartans+equal
Are+all+sartans+equalAre+all+sartans+equal
Are+all+sartans+equal
 
Anti-Hypertensive drugs
Anti-Hypertensive drugsAnti-Hypertensive drugs
Anti-Hypertensive drugs
 
Anti anginal drugs
Anti anginal drugsAnti anginal drugs
Anti anginal drugs
 
Calcium Channel Blockers in Hypertension
Calcium Channel Blockers in Hypertension Calcium Channel Blockers in Hypertension
Calcium Channel Blockers in Hypertension
 
Positive inotropes, vasopressors, and vasodilators
Positive inotropes, vasopressors, and vasodilatorsPositive inotropes, vasopressors, and vasodilators
Positive inotropes, vasopressors, and vasodilators
 
Fusaro - Renal Denervation, current evidence and new technical developments
Fusaro - Renal Denervation, current evidence and new technical developmentsFusaro - Renal Denervation, current evidence and new technical developments
Fusaro - Renal Denervation, current evidence and new technical developments
 
Antianginal Drugs
Antianginal DrugsAntianginal Drugs
Antianginal Drugs
 
Tolvaptan
TolvaptanTolvaptan
Tolvaptan
 
ARBs USE IN MANAGEMENT OF MYORCARDIAL INFARCTION
ARBs USE IN MANAGEMENT OF MYORCARDIAL INFARCTIONARBs USE IN MANAGEMENT OF MYORCARDIAL INFARCTION
ARBs USE IN MANAGEMENT OF MYORCARDIAL INFARCTION
 
Anti anginal drugs
Anti  anginal drugsAnti  anginal drugs
Anti anginal drugs
 
ACE-I in heart failure
ACE-I in heart failureACE-I in heart failure
ACE-I in heart failure
 
inotropes 2
inotropes 2inotropes 2
inotropes 2
 
Vasoactve drugs
Vasoactve  drugsVasoactve  drugs
Vasoactve drugs
 
Vasodilator Lecture
Vasodilator LectureVasodilator Lecture
Vasodilator Lecture
 
Paradigm hf-trial-ppt-pptx - copia
Paradigm hf-trial-ppt-pptx - copiaParadigm hf-trial-ppt-pptx - copia
Paradigm hf-trial-ppt-pptx - copia
 
current practice for use of inotropes post adult cardiac surgery
current practice for use of inotropes post adult cardiac surgerycurrent practice for use of inotropes post adult cardiac surgery
current practice for use of inotropes post adult cardiac surgery
 
OSCAR trial - Summary & Results
OSCAR trial - Summary & ResultsOSCAR trial - Summary & Results
OSCAR trial - Summary & Results
 
Inotropes and their choice
Inotropes and their choiceInotropes and their choice
Inotropes and their choice
 
Telsarta-A final-01-04-16
Telsarta-A  final-01-04-16Telsarta-A  final-01-04-16
Telsarta-A final-01-04-16
 

Viewers also liked

Leo Dijkema's presenatie namens Pentascope
Leo Dijkema's presenatie namens PentascopeLeo Dijkema's presenatie namens Pentascope
Leo Dijkema's presenatie namens PentascopeWOW! Het kan anders
 
160125 Diploma de Experto Universitario - Gestión Directiva de ONL
160125 Diploma de Experto Universitario - Gestión Directiva de ONL160125 Diploma de Experto Universitario - Gestión Directiva de ONL
160125 Diploma de Experto Universitario - Gestión Directiva de ONLSergio Gallego Schmid
 
Exact live 2015: Groeistrategieën webshop door Bas van der Lans
Exact live 2015: Groeistrategieën webshop door Bas van der LansExact live 2015: Groeistrategieën webshop door Bas van der Lans
Exact live 2015: Groeistrategieën webshop door Bas van der LansBas van der Lans
 
Straddlingbusbyrk 150515005107-lva1-app6892
Straddlingbusbyrk 150515005107-lva1-app6892Straddlingbusbyrk 150515005107-lva1-app6892
Straddlingbusbyrk 150515005107-lva1-app6892Juan Leyva Dominguez
 
HDLG - HELP Ze vinden alles goed!
HDLG - HELP Ze vinden alles goed!HDLG - HELP Ze vinden alles goed!
HDLG - HELP Ze vinden alles goed!WOW! Het kan anders
 
Validação de Voltímetro Via Regressão
Validação de Voltímetro Via RegressãoValidação de Voltímetro Via Regressão
Validação de Voltímetro Via RegressãoMarcos
 
Boek over social media in de bouw: Van weerstand naar transparant
Boek over social media in de bouw: Van weerstand naar transparantBoek over social media in de bouw: Van weerstand naar transparant
Boek over social media in de bouw: Van weerstand naar transparantIngesijpkens.nl
 
Bmc news 1997 spring
Bmc news 1997 springBmc news 1997 spring
Bmc news 1997 springjohnadam521
 
Etiqueta para niños.
Etiqueta para niños.Etiqueta para niños.
Etiqueta para niños.LeidyKellys
 
René Lievens & Frits Slingerland - Simpel Anders doen
René Lievens & Frits Slingerland - Simpel Anders doenRené Lievens & Frits Slingerland - Simpel Anders doen
René Lievens & Frits Slingerland - Simpel Anders doenWOW! Het kan anders
 
Smart Grid no Brasil: Até quando esperar?
Smart Grid no Brasil: Até  quando esperar?Smart Grid no Brasil: Até  quando esperar?
Smart Grid no Brasil: Até quando esperar?Marcos
 
DOON - Innoveren als een start-up
DOON - Innoveren als een start-upDOON - Innoveren als een start-up
DOON - Innoveren als een start-upWOW! Het kan anders
 
Solid waste management
Solid waste managementSolid waste management
Solid waste managementNabeela Basha
 
Certificado titulo uned
Certificado titulo unedCertificado titulo uned
Certificado titulo unedAdriana Rivera
 
solid waste management by abrar saleem
solid waste management by abrar saleemsolid waste management by abrar saleem
solid waste management by abrar saleemjunaid bashir
 
Big data for development
Big data for development Big data for development
Big data for development Junaid Qadir
 

Viewers also liked (19)

Leo Dijkema's presenatie namens Pentascope
Leo Dijkema's presenatie namens PentascopeLeo Dijkema's presenatie namens Pentascope
Leo Dijkema's presenatie namens Pentascope
 
ไหลเรือไฟ
ไหลเรือไฟไหลเรือไฟ
ไหลเรือไฟ
 
Thesis 1 abstract
Thesis 1 abstractThesis 1 abstract
Thesis 1 abstract
 
160125 Diploma de Experto Universitario - Gestión Directiva de ONL
160125 Diploma de Experto Universitario - Gestión Directiva de ONL160125 Diploma de Experto Universitario - Gestión Directiva de ONL
160125 Diploma de Experto Universitario - Gestión Directiva de ONL
 
Exact live 2015: Groeistrategieën webshop door Bas van der Lans
Exact live 2015: Groeistrategieën webshop door Bas van der LansExact live 2015: Groeistrategieën webshop door Bas van der Lans
Exact live 2015: Groeistrategieën webshop door Bas van der Lans
 
Exec Summary_CYT
Exec Summary_CYTExec Summary_CYT
Exec Summary_CYT
 
Straddlingbusbyrk 150515005107-lva1-app6892
Straddlingbusbyrk 150515005107-lva1-app6892Straddlingbusbyrk 150515005107-lva1-app6892
Straddlingbusbyrk 150515005107-lva1-app6892
 
HDLG - HELP Ze vinden alles goed!
HDLG - HELP Ze vinden alles goed!HDLG - HELP Ze vinden alles goed!
HDLG - HELP Ze vinden alles goed!
 
Validação de Voltímetro Via Regressão
Validação de Voltímetro Via RegressãoValidação de Voltímetro Via Regressão
Validação de Voltímetro Via Regressão
 
Boek over social media in de bouw: Van weerstand naar transparant
Boek over social media in de bouw: Van weerstand naar transparantBoek over social media in de bouw: Van weerstand naar transparant
Boek over social media in de bouw: Van weerstand naar transparant
 
Bmc news 1997 spring
Bmc news 1997 springBmc news 1997 spring
Bmc news 1997 spring
 
Etiqueta para niños.
Etiqueta para niños.Etiqueta para niños.
Etiqueta para niños.
 
René Lievens & Frits Slingerland - Simpel Anders doen
René Lievens & Frits Slingerland - Simpel Anders doenRené Lievens & Frits Slingerland - Simpel Anders doen
René Lievens & Frits Slingerland - Simpel Anders doen
 
Smart Grid no Brasil: Até quando esperar?
Smart Grid no Brasil: Até  quando esperar?Smart Grid no Brasil: Até  quando esperar?
Smart Grid no Brasil: Até quando esperar?
 
DOON - Innoveren als een start-up
DOON - Innoveren als een start-upDOON - Innoveren als een start-up
DOON - Innoveren als een start-up
 
Solid waste management
Solid waste managementSolid waste management
Solid waste management
 
Certificado titulo uned
Certificado titulo unedCertificado titulo uned
Certificado titulo uned
 
solid waste management by abrar saleem
solid waste management by abrar saleemsolid waste management by abrar saleem
solid waste management by abrar saleem
 
Big data for development
Big data for development Big data for development
Big data for development
 

Similar to 2015-EB-Math Model RVP increase_austin-bb2

20 Saxena Acute Renal Failure
20 Saxena   Acute Renal Failure20 Saxena   Acute Renal Failure
20 Saxena Acute Renal FailureDang Thanh Tuan
 
Renal blood flow and its regulation
Renal blood flow and its regulation Renal blood flow and its regulation
Renal blood flow and its regulation Ahmad Ozair
 
Renal stenting and denervation - prof. Tadeusz Przewłocki
Renal stenting and denervation - prof. Tadeusz PrzewłockiRenal stenting and denervation - prof. Tadeusz Przewłocki
Renal stenting and denervation - prof. Tadeusz Przewłockipiodof
 
Acute renal failure
Acute renal failureAcute renal failure
Acute renal failureShahab Riaz
 
Electrolyte dysbalance in chf – prognosis & management
Electrolyte dysbalance  in chf – prognosis & managementElectrolyte dysbalance  in chf – prognosis & management
Electrolyte dysbalance in chf – prognosis & managementArindam Pande
 
Angiotensin Receptor Neprilysin + Valsartan
Angiotensin Receptor Neprilysin + ValsartanAngiotensin Receptor Neprilysin + Valsartan
Angiotensin Receptor Neprilysin + ValsartanJai Parekh
 
Prof .Aziz-ur-Rehman
Prof .Aziz-ur-RehmanProf .Aziz-ur-Rehman
Prof .Aziz-ur-RehmanPk Doctors
 
Recent advances in management of heart failure
Recent advances in management of heart failureRecent advances in management of heart failure
Recent advances in management of heart failurerahul arora
 
Imaging of kidny i htn by dr.abd alla shady md
Imaging of kidny i htn by dr.abd alla shady mdImaging of kidny i htn by dr.abd alla shady md
Imaging of kidny i htn by dr.abd alla shady mdFarragBahbah
 
Acute Heart Failure – The road to where
Acute Heart Failure – The road to whereAcute Heart Failure – The road to where
Acute Heart Failure – The road to wheredrucsamal
 
How Best To Prevent & Manage Acute Renal failure
How Best To Prevent & Manage Acute Renal failureHow Best To Prevent & Manage Acute Renal failure
How Best To Prevent & Manage Acute Renal failurechandra talur
 
Haemodynamic management in liver surgery
Haemodynamic management in liver surgeryHaemodynamic management in liver surgery
Haemodynamic management in liver surgeryscanFOAM
 
Hepatorenal syndrome
Hepatorenal syndromeHepatorenal syndrome
Hepatorenal syndromeAkshay Goel
 
06 Paden Acute Renal Failure
06 Paden   Acute Renal Failure06 Paden   Acute Renal Failure
06 Paden Acute Renal FailureDang Thanh Tuan
 
06 Paden Acute Renal Failure
06 Paden   Acute Renal Failure06 Paden   Acute Renal Failure
06 Paden Acute Renal Failureguest2379201
 
Nitrates and Vericiguat in heart failure
Nitrates and Vericiguat in heart failureNitrates and Vericiguat in heart failure
Nitrates and Vericiguat in heart failureAmit Gulati
 
Class drug therapy of shock
Class drug therapy of shockClass drug therapy of shock
Class drug therapy of shockRaghu Prasada
 
Use of echocardiography in icu
Use of echocardiography in icuUse of echocardiography in icu
Use of echocardiography in icuNisheeth Patel
 

Similar to 2015-EB-Math Model RVP increase_austin-bb2 (20)

20 Saxena Acute Renal Failure
20 Saxena   Acute Renal Failure20 Saxena   Acute Renal Failure
20 Saxena Acute Renal Failure
 
Renal blood flow and its regulation
Renal blood flow and its regulation Renal blood flow and its regulation
Renal blood flow and its regulation
 
Renal stenting and denervation - prof. Tadeusz Przewłocki
Renal stenting and denervation - prof. Tadeusz PrzewłockiRenal stenting and denervation - prof. Tadeusz Przewłocki
Renal stenting and denervation - prof. Tadeusz Przewłocki
 
Acute renal failure
Acute renal failureAcute renal failure
Acute renal failure
 
ARB in the management of Hypertension
ARB in the management of HypertensionARB in the management of Hypertension
ARB in the management of Hypertension
 
Electrolyte dysbalance in chf – prognosis & management
Electrolyte dysbalance  in chf – prognosis & managementElectrolyte dysbalance  in chf – prognosis & management
Electrolyte dysbalance in chf – prognosis & management
 
Angiotensin Receptor Neprilysin + Valsartan
Angiotensin Receptor Neprilysin + ValsartanAngiotensin Receptor Neprilysin + Valsartan
Angiotensin Receptor Neprilysin + Valsartan
 
Mech Ventilation basics.pptx
 Mech Ventilation basics.pptx Mech Ventilation basics.pptx
Mech Ventilation basics.pptx
 
Prof .Aziz-ur-Rehman
Prof .Aziz-ur-RehmanProf .Aziz-ur-Rehman
Prof .Aziz-ur-Rehman
 
Recent advances in management of heart failure
Recent advances in management of heart failureRecent advances in management of heart failure
Recent advances in management of heart failure
 
Imaging of kidny i htn by dr.abd alla shady md
Imaging of kidny i htn by dr.abd alla shady mdImaging of kidny i htn by dr.abd alla shady md
Imaging of kidny i htn by dr.abd alla shady md
 
Acute Heart Failure – The road to where
Acute Heart Failure – The road to whereAcute Heart Failure – The road to where
Acute Heart Failure – The road to where
 
How Best To Prevent & Manage Acute Renal failure
How Best To Prevent & Manage Acute Renal failureHow Best To Prevent & Manage Acute Renal failure
How Best To Prevent & Manage Acute Renal failure
 
Haemodynamic management in liver surgery
Haemodynamic management in liver surgeryHaemodynamic management in liver surgery
Haemodynamic management in liver surgery
 
Hepatorenal syndrome
Hepatorenal syndromeHepatorenal syndrome
Hepatorenal syndrome
 
06 Paden Acute Renal Failure
06 Paden   Acute Renal Failure06 Paden   Acute Renal Failure
06 Paden Acute Renal Failure
 
06 Paden Acute Renal Failure
06 Paden   Acute Renal Failure06 Paden   Acute Renal Failure
06 Paden Acute Renal Failure
 
Nitrates and Vericiguat in heart failure
Nitrates and Vericiguat in heart failureNitrates and Vericiguat in heart failure
Nitrates and Vericiguat in heart failure
 
Class drug therapy of shock
Class drug therapy of shockClass drug therapy of shock
Class drug therapy of shock
 
Use of echocardiography in icu
Use of echocardiography in icuUse of echocardiography in icu
Use of echocardiography in icu
 

2015-EB-Math Model RVP increase_austin-bb2

  • 1. Aim:     To  inves)gate  how  changes  in  renal  arterial  pressure  and  venous   pressure  separately  and  in  combina)on  affect  renal   hemodynamic  and  re-­‐absorp)ve  func)on,  in  simulated  states  of   normal,  elevated  and  strongly  elevated  levels  of  Angiotensin  II   (Ang  II).   Background:     Heart  failure  (HF)  is  associated  with  impaired  renal  func)on.  This   has  been  aCributed  to  systemic  hemodynamic  changes:  forward   failure  causing  decreased  renal  arterial  pressure  (RAP)  and   backward  failure  causing  venous  conges)on  and  increased  renal   venous  pressure  (RVP).     Aus)n  Baird1,  Branko  Braam2  and  Anita  Layton1     1  Dept.  Mathema)cs,  Duke  Univ.,  Durham,  NC,  USA  and  2  Div.  Nephrology,  Dept.  Medicine  and  Dept.  Physiology,  Univ.  of  Alberta,  Edmonton,  AB,  Canada   Conclusion:   Our  model  implicates  that  a  decrease  in  renal  arterial  pressure  leads  to  a   decrease   in   sodium   excre)on   under   normal   condi)ons,   which   becomes   more  pronounced  when  venous  pressure  is  increased.  Angiotensin  II  leads   to   a   depression   of   GFR,   and   to   a   strong   decrease   in   frac)onal   sodium   excre)on.   Further   studies   will   be   directed   to   inves)gate   the   role   of   the   myogenic  response  and  tubuloglomerular  feedback  on  renal  func)on  and   response  to  changes  in  renal  arterial  and  venous  pressures.       This   research   was   supported   in   part   by   NIH   grant   DK-­‐89066   and   by   NSF   grant  DMS1263995   Implica)ons  of  increased  renal  venous  pressure  for  renal  hemodynamic  and   reabsorp)ve  func)on  studied  by  a  mathema)cal  model  of  the  kidney   IM:  Inner  medulla;  CDs:  collec)ng  ducts;  MD:  macula  densa;  PCT:   proximal  convoluted  tubule;  DVR:  descending  vasa  recta;  AVR:   ascending  vasa  recta.   RVP (mmHg) 5 10 15 20 25 30 RAP (mmHg) 80 100 120 SNGFR(nl min) 0 5 10 15 20 25 30 35 5 10 15 20 25 30 RVP (mmHg) 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 Sodiumexcretion(umol/min) baseline low high 5 10 15 20 25 30 RVP (mmHg) 50 100 150 200 250 300 350 400 SNBF(nl/min) baseline low high 5 10 15 20 25 30 RVP (mmHg) 0.0 0.1 0.2 0.3 0.4 0.5 0.6 FractionalNaexcretion(%) baseline low high 80 100 120 140 160 180 200 RAP (mmHg) 0 2 4 6 8 10 Sodiumexcretion(umol/min) baseline low high RVP (mmHg) 5 10 15 20 25 30 RAP (mmHg) 80 100 120 SNGFR(nl min) 0 5 10 15 20 25 30 35 Inner   stripe   Inner   medulla   Outer   stripe   Renal  Venous   Pressure  (RVP)   Renal  Arterial   Pressure  (RAP)   RVP (mmHg) 5 10 15 20 25 30 RAP (mmHg) 80 100 120 FractionalNaexcretion% 0.0 0.2 0.4 0.6 0.8 1.0 1.2 Cortex   RVP (mmHg) 5 10 15 20 25 30 RAP (mmHg) 80 100 120 FractionalNaexcretion% 0.0 0.2 0.4 0.6 0.8 1.0 1.2 RVP (mmHg) 5 10 15 20 25 30 RAP (mmHg) 80 100 120 FractionalNaexcretion% 0.0 0.2 0.4 0.6 0.8 1.0 1.2 High  Ang  II   Figure   2:   SNGFR   and   SNBF,   obtained   for   the   superficial   nephron,   whole   kidney  sodium  excre)on  and  frac)onal  sodium  excre)on  dependency  on   RVP  in  normal  (baseline),  elevated  (low)  and  strongly  (high)  elevated  Ang  II   states.  RAP  =  100  mmHg  for  all  simula)ons.   RVP (mmHg) 5 10 15 20 25 30 RAP (mmHg) 80 100 120 SNGFR(nl min) 0 5 10 15 20 25 30 35 Figure  3:  Effects  on  SNGFR  and  frac)onal  whole  kidney  sodium  excre)on   upon  combined  changes  of  RAP  and  RVP  in  normal  (baseline),  elevated   (low)  and  very  elevated  (high)  Ang  II  states.  SNGFR  reported  for  the   superficial  nephron  simula)ons.   Baseline   Low  Ang  II   Renal  Venous   Pressure  (RVP)   80 100 120 140 160 180 200 RAP (mmHg) 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 FractionalNaexcretion(%) baseline low high 80 100 120 140 160 180 200 RAP (mmHg) 10 20 30 40 50 60 70 SNGFR(nl/min) baseline low high 80 100 120 140 160 180 200 RAP (mmHg) 150 200 250 300 350 400 450 SNBF(nl/min) baseline low high 5 10 15 20 25 30 RVP (mmHg) 0 10 20 30 40 50 60 SNGFR(nl/min) baseline low high References:   1.  R  Moss  and  AT  Layton,  AJP  Renal,  2014.   Methods:     We  used  a  published  and  well-­‐characterized  mathema)cal   kidney  model  incorpora)ng  superficial  and  deep  nephrons  and   renal  hemodynamics,  including  myogenic  response  (MR),  tubulo-­‐ glomerular  feedback  (TGF),  and  segmental  sodium  handling  [1].     Figure  1:  Single  nephron  GFR  (SNGFR)  blood  flow  (SNBF),  both  obtained  for   the  superficial  nephron,  and  whole  kidney  sodium  excre)on  and  frac)onal   sodium  excre)on  dependency  on  renal  artery  pressure  (RAP)  in  normal   (baseline),  elevated  (low)  and  strongly  (high)  elevated  Ang  II  states.  RVP  =  5   mmHg  for  all  simula)ons.